Researchers at Weill Cornell Medicine have discovered how drugs can affect various membrane-spanning proteins in addition to their intended target, potentially causing unwanted side effects. The results illuminate one of the central problems of drug discovery and point to new strategies for solving it. Any class of drug can have side effects, but those that […]
Home »
Freiburg immunologists decipher anti-cancer drug's mode of operation
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients to investigate how […]